Postmenopausal hormone replacement therapy and cardiovascular risk: Role of conjugated equine estrogens and medroxyprogesterone acetate;Einfluss postmenopausaler hormonsubstitution mit konjugierten equinen östrogenen und medroxyprogesteronazetat auf das kardiovaskuläre risiko

Praxis

Volumn 93, Issue 21, 2004, Pages 904-914

  Ortmann, J ^a   Traupe, T ^a   Vetter, W ^a   Barton, M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Coronary artery disease; Hormone replacement therapy; Medroxyprogesterone acetate; Menopause; Thrombosis

Indexed keywords

EID: 80051758881     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.93.21.904     Document Type: Review

References (125)

1. Virchow R. Der atheromatöse Prozess der Arterien. Wien Med Wochenschr 1856; 6 (51): 809-812.
2. Gotto AM, Farmer JA. Risk factors for coronary artery disease. In: Braunwald, editor. Heart Disease. Philadelphia:W.B. Saunders Co.; 1992. p. 1125- 60.
3. Ross R. The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature 1993; 362 (6423): 801-9.
4. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2 (8618): 983-6.
5. Ross R. The pathogenesis of atherosclerosis. In: Braunwald E, editor. Heart Disease. Philadelphia:W.B. Saunders; 1992. p. 1106-24.
6. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102 (8): 833-9.
7. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103 (8): 1064-70. (Pubitemid 32200178)
8. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. Circulation 2001; 103 (10): 1390-5. (Pubitemid 32220630)
9. Barton M, Haudenschild CC. Endothelium and atherogenesis: endothelial therapy revisited. J Cardiovasc Pharmacol 2001; 38 Suppl 2: S 23-5.
10. Traupe T, Ortmann J, Münter K, Barton M. Endothelial Therapy of Atherosclerosis and its Risk Factors. Current Vascular Pharmacology 2003; 1: 111- 121.
11. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E- deficient mice. Proc Natl Acad Sci USA 1996; 93 (19): 10022-7.
12. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340 (23): 1801-11. (Pubitemid 29266405)
13. Parrish HM, Carr CA, Hall DG, King TM. Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol 1967; 99 (2): 155-62.
14. Engel HJ, Page HL, Campbell WB. Coronary artery disease in young women. Jama 1974; 230 (11): 1531-4.
15. Witteman JCM, Grobbee DE, Kok FJ, Hofman A, Valkenburg HA. Increased risc of atherosclerosis in women after the menopause. Br Med J 1989; 298: 642-4. (Pubitemid 19088522)
16. Punnonen R, Jokela H, Aine R, Teisala K, Salomaki A, Uppa H. Impaired ovarian function and risk factors for atherosclerosis in premenopausal women. Maturitas 1997; 27 (3): 231-8. (Pubitemid 27356255)
17. Manchester JH, Herman MV, Gorlin R. Premenopausal castration and documented coronary atherosclerosis. Am J Cardiol 1971; 28 (1): 33-7.
18. Trumbull HR, Sako Y. Augmentation of experimental atherogenesis by oophorectomy. Surg Forum 1974; 25 (0): 206-9.
19. Weiss NS. Premature menopause and aortoiliac occlusive disease. J Chronic Dis 1972; 25 (3): 133-8.
20. Pick R. The inhibition of coronary atheromatosis in cholesterol-fed chicken receiving estrogen. Circulation 1951; 4: 468.
21. Lorenzen I, Schiff M. Vascular connective tissue under the influence of oestrogens. 3. Effect of oestrogens on experimental arteriosclerosis. Morphological and biochemical studies. Acta Endocrinol (Copenh) 1968; 57 (3): 457- 64.
22. Ho KJ, Manalo-Estrella P, Taylor CB. Female sex hormones. Effect on aortic acid mucopolysaccharides and atherosclerosis in rabbits. Arch Pathol 1970; 90 (2): 129-36.
23. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on endothelium- dependent responses in the rabbit. J Pharmacol Exp Ther 1988; 244 (1): 19-22. (Pubitemid 18042356)
24. Miller VM, Vanhoutte PM. 17 beta-Estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol 1990; 258 (6 Pt 2): R 1502-7.
25. Barton M, Cremer J, Mugge A. 17Beta-estradiol acutely improves endothelium- dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol 1998; 362 (1): 73-6. (Pubitemid 29000999)
26. Gisclard V, Flavahan NA, Vanhoutte PM. Alpha adrenergic responses of blood vessels of rabbits after ovariectomy and administration of 17 beta-estradiol. J Pharmacol Exp Ther 1987; 240 (2): 466-70. (Pubitemid 17018427)
27. Seely EW,Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33 (5): 1190-4. (Pubitemid 29230972)
28. Barr DP, Russ EM, Eder HA. Influence of estrogen on lipoproteins in atherosclerosis. Trans Assoc Amer Phys 1952; 65: 102-113.
29. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. BMJ 1996; 312 (7029): 473-8.
30. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. J Am Med Assoc 1995; 273 (3): 199-208.
31. Farish E, Rolton HA, Barnes JF, Fletcher CD,Walsh DJ, Spowart KJ, et al. Lipoprotein (a) and postmenopausal oestrogen. Acta Endocrinol (Copenh) 1993; 129 (3): 225-8.
32. van der Mooren MJ, Demacker PN, Thomas CM, Rolland R. Beneficial effects on serum lipoproteins by 17 beta-oestradiol- dydrogesterone therapy in postmenopausal women; a prospective study. Eur J Obstet Gynecol Reprod Biol 1992; 47 (2): 153-60.
33. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 2000; 283 (14): 1845-52. (Pubitemid 30207621)
34. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J 2001; 141 (2 Pt 2): 58-62.
35. Barton M, Kockx M. Estrogen and apoptosis in atherosclerosis. In: Samsioe G, Skouby S (editors.) Midlife Health - Current Concepts and Challenges for the Future. Elsevier Science (2002): 81-93.
36. Giri S, Thompson PD, Taxel P, Contois JH, Otvos J, Allen R, et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998; 137 (2): 359-66.37.
37. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996; 93 (11): 1970-5.
38. Gebara OC, Mittleman MA,Walsh BW, Lipinska I,Welty FK, Bellotti G, et al. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998; 80 (3): 235-9. (Pubitemid 28440340)
39. .Weitz G, Elam M, Born J, Fehm HL, Dodt C. Postmenopausal Estrogen Administration Suppresses Muscle Sympathetic Nerve Activity. J Clin Endocrinol Metab 2001; 86 (1): 344-348. (Pubitemid 32109816)
40. Farhat MY, Abi-Younes S, Ramwell PW. Non-genomic effects of estrogen and the vessel wall. Biochem Pharmacol 1996; 51 (5): 571-6. (Pubitemid 26080131)
41. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104 (5): 719- 30.
42. Harder DR, Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol 1979; 100 (2): 375-82. (Pubitemid 9251387)
43. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol- 3-OH kinase. Nature 2000; 407 (6803): 538-41.
44. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 2000; 97 (11): 5930- 5.
45. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87 (8): 677-82.
46. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997; 273 (1 Pt 1): L119-26.
47. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103 (3): 401-6. (Pubitemid 29069990)
48. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR. 17bestradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997; 81: 885-92. (Pubitemid 27467225)
49. Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1999; 96 (6): 2788-93. (Pubitemid 29148796)
50. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: : how does It Work? what does It mean? Circ Res 2000; 87 (11): 956-60.
51. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium- independent relaxation of rabbit coronary artery by 17 beta- oestradiol in vitro. Br J Pharmacol 1991; 104 (4): 1033-7.
52. Mügge A, Riedel M, Barton M, Kuhn M, Lichtlen PR. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res 1993; 27 (11): 1939-42. (Pubitemid 23357336)
53. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P. Oestrogen relaxes human epicardial coronary arteries through non- endothelium-dependent mechanisms. Coron Artery Dis 1995; 6 (5): 417-22.
54. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135 (11): 939-53. (Pubitemid 33131615)
55. Selzer RH, Mack WJ, Lee PL, Kwong-Fu H, Hodis HN. Improved common carotid elasticity and intima-media thickness measurements from computer analysis of sequential ultrasound frames. Atherosclerosis 2001; 154 (1): 185- 93.
56. Hodis HN, Mack WJ, R.A. L, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the Prevention of Atherosclerosis Trial. Circulation 2000; 102 (Suppl. II): II-836.
57. Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol 2000; 36 (6): 1789-96.
58. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99 (18): 2434-9. (Pubitemid 29218240)
59. WHISP.Women's Hormones Intervention Secondary Prevention Trial. URL: http://www.ihs.ox.ac.uk/herc/research/trials/whisp.shtml.
60. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (7): 605-13. (Pubitemid 28502636)
61. Investigators WGftWsHI. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333.
62. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary- artery atherosclerosis. N Engl J Med 2000; 343 (5): 522-9. (Pubitemid 30650747)
63. Wilson PW. Lower diabetes risk with hormone replacement therapy: an encore for estrogen? Ann Intern Med 2003; 138 (1): 69-70. (Pubitemid 36232096)
64. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/ progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138 (1): 1-9. (Pubitemid 36232088)
65. Jensen Ev, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18: 387-414.
66. Barton M, Dubey RK. Postmenopausal hormone-replacement therapy. N Engl J Med 2002; 346 (1): 63-5.
67. Dubey RK, Gillespie DG, Jackson EK, Keller PJ. 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 1998; 31 (1 Pt 2): 522-8.
68. Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA, Jackson EK, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 1999; 84 (2): 229-39. (Pubitemid 29070119)
69. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J, et al. Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun 2000; 278 (1): 27-33.
70. Dubey RK, Gillespie DG, Mi Z, Rosselli M, Keller PJ, Jackson EK. Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. Hypertension 2000; 35 (1 Pt 2): 262-6.71.
71. Xiao S, Gillespie DG, Baylis C, Jackson EK, Dubey RK. Effects of Estradiol and Its Metabolites on Glomerular Endothelial Nitric Oxide Synthesis and Mesangial Cell Growth. Hypertension 2001; 37 (2 Part 2): 645-650.
72. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001; 37 (2 Part 2): 640-644. (Pubitemid 32199042)
73. Seeger H,Wallwiener D, Mueck AO. Effect of medroxyprogesterone acetate and norethisterone on serum- stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. Menopause 2001; 8 (1): 5-9. (Pubitemid 32066574)
74. Zhu X, Bonet B, Knopp RH. Estradiol 17beta inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees. Atherosclerosis 2000; 148 (1): 31-41.
75. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells. Cancer Lett 1999; 141 (1-2): 63- 71.
76. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998; 18 (7): 1164-71. (Pubitemid 28323602)
77. Adams MR, Register TC, Golden DL,Wagner JD, Williams KD. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217-21. (Pubitemid 27057346)
78. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 1996; 94 (9): 2221-7. (Pubitemid 26360517)
79. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3 (3): 324-7. (Pubitemid 27112931)
80. Rosano GM,Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000; 36 (7): 2154-9.
81. Kawano H, Motoyama T, Hirai N, Yoshimura T, Kugiyama K, Ogawa H, et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium- dependent vasodilation in postmenopausal women. Am J Cardiol 2001; 87 (2): 238-40, A9.
82. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133 (12): 933-41. (Pubitemid 32003509)
83. .Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289 (20): 2673-84. (Pubitemid 37430138)
84. Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl 1984; 127: 1-37.
85. Adams MR, Register TC, Golden DL,Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17 (1): 217-21. (Pubitemid 27057346)
86. Wils JA, Bron H, Van Lange L, Pannebakker M, Romme A, Scheerder H, et al. A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high-dose medroxyprogesteron acetate in advanced breast cancer. Cancer 1985; 56 (6): 1325-31. (Pubitemid 15230577)
87. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH,Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75 (6): 1102-9. (Pubitemid 17081015)
88. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316 (18): 1105-10. (Pubitemid 17052498)
89. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151 (1): 75-8.
90. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991; 325 (11): 756- 62.
91. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164 (2): 489-94.
92. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335 (7): 453-61. (Pubitemid 26269944)
93. Silvestri A, Gebara O, Vitale C,Wajngarten M, Leonardo F, Ramires JA, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107 (25): 3165-9.
94. Reed MJ, Murray MAF. The oestrogens. In: Gray CH JVx, editor. Hormones in blood. London; 1979. p. 263-353.
95. Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 2002; 78 (6): 1178-83. (Pubitemid 35463111)
96. Clark JR, Dierschke DJ,Wolf RC. Hormonal regulation of ovarian folliculogenesis in rhesus monkeys: III. Atresia of the preovulatory follicle induced by exogenous steroids and subsequent follicular development. Biol Reprod 1981; 25 (2): 332-41. (Pubitemid 11029394)
97. Good AE. Hormone therapy in menopause: the plot thickens. Minn Med 2003; 86 (1): 32-5.
98. Schneider HP. Hormonersatztherapie - weniger ist oft mehr. Zentralbl Gynakol 2001; 123 (9): 546-7. (Pubitemid 32980080)
99. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-aweek 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002; 9 (3): 195-207. (Pubitemid 34492328)
100. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Ciruclation 1997; 95: 39-45. (Pubitemid 27029940)
101. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003; 88 (6): 2470-8.
102. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20 (5): 1404-9.
103. Wessler S. Estrogen-associated thromboembolism. Ann Epidemiol 1992; 2 (4): 439-43.
104. Bagdade JD, Subbaiah PV. Atherosclerosis and oral contraceptive use. Serum from oral contraceptive users stimulates growth of arterial smooth muscle cells. Arteriosclerosis 1982; 2 (2): 170-6. (Pubitemid 12084418)
105. L'Hermite M. Risks of estrogens and progestogens. Maturitas 1990; 12 (3): 215-46.
106. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. J Am Med Assoc 1978; 240 (23): 2548-52. (Pubitemid 9092601)
107. Burkman RT. The estrogen component of oral contraceptives: cardiovascular benefits and risks. Int J Fertil Womens Med 1997; Suppl(1): 145-57.
108. Winkler UH. Hormone replacement therapy and hemostasis: principles of a complex interaction. Maturitas 1996; 24 (3): 131-45.
109. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J Am Med Assoc 1979; 242 (11): 1150-4. (Pubitemid 10231673)
110. Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000; 343 (8): 530-7. (Pubitemid 30650748)
111. Manson JE, Hu FB, Rich-Edwards JW, Colditz GA, Stampfer MJ, Willett WC, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341 (9): 650-8. (Pubitemid 29399044)
112. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343 (1): 16-22. (Pubitemid 30447987)
113. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285 (7): 906-13. (Pubitemid 32171552)
114. Hsia J, Simon JA, Lin F, Applegate WB, Vogt MT, Hunninghake D, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102 (18): 2228-32.
115. Shlipak MK, Go AS, Angeja B, Frederick PD, Canto JG, Grady D. The association of post-menopausal estrogen therapy with survival after myocardial infarction. Circulation 2001; 104 (19): 2300-2304 (Pubitemid 33049512)
116. Angerer P, Störk S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progresson of athersclerosis: A randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 262-8. (Pubitemid 32125376)
117. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal Hormone Therapy and Risk of Stroke : The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001; 103 (5): 638-642. (Pubitemid 32144190)
118. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348 (7): 618-29. (Pubitemid 36210865)
119. Le Gal G, Gourlet V, Hogrel P, Plu-Bureau G, Touboul PJ, Scarabin PY. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis 2003; 166 (1): 163-70. (Pubitemid 35449612)
120. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Ostet Gynecol 2002; 109 (9): 1056-62. (Pubitemid 35279139)
121. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345 (17): 1243-9. (Pubitemid 34951488)
122. Mack,W. J., A. B. Hameed, et al. (2003). Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. Atherosclerosis 168(1): 91-8. (Pubitemid 36555815)
123. Hodis, H. N.,W. J. Mack, et al. (2003). Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.N Engl J Med 349 (6): 535-45. (Pubitemid 36951365)
124. Powledge TM: NIH terminates WHI oestrogen - only study Lancet 2004; 363 (9412): 870.
125. Mosca, L. Heart disease prevention in women. Circulation 2004; 109: e158-e160.